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Abstract: Diabetes mellitus is a widespread disease, and represents an important public health
burden worldwide. Together with cardiovascular, renal and neurological complications, many
patients with diabetes present with gastrointestinal symptoms, which configure the so-called diabetic
enteropathy. In this review, we will focus on upper gastrointestinal symptoms in patients with
diabetes, with particular attention to dyspepsia and diabetic gastroparesis (DG). These two clinical
entities share similar pathogenetic mechanisms, which include autonomic neuropathy, alterations
in enteric nervous system and histological abnormalities, such as interstitial cells of Cajal depletion.
Moreover, the differential diagnosis may be challenging because of overlapping clinical features.
Delayed gastric emptying should be documented to differentiate between DG and dyspepsia and
it can be assessed through radioactive or non-radioactive methods. The clinical management of
dyspepsia includes a wide range of different approaches, above all Helicobacter pylori test and treat.
As regards DG treatment, a central role is played by dietary modification and glucose control and the
first-line pharmacological therapy is represented by the use of prokinetics. A minority of patients with
DG refractory to medical treatment may require more invasive therapeutic approaches, including
supplemental nutrition, gastric electric stimulation, pyloromyotomy and gastrectomy.
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1. Introduction
Diabetes mellitus (DM) is a widespread disease. According to the last estimate from
the International Diabetes Federation (ID) it affects 463 million people worldwide with in-
creasing prevalence [1]. DM represents an important public health burden, mainly because
of its cardiovascular, renal and neurological complications. In addition, many patients
with diabetes present with upper gastrointestinal (GI) symptoms and motility alterations.
Among the latter, delayed gastric emptying (GE) affects up to 50% of patients with both
type 1 and type 2 DM manifesting with dyspepsia, gastroparesis or, for a proportion of
patients, remaining asymptomatic [2]. As dyspepsia and diabetic gastroparesis (DG) share
similar pathogenetic mechanisms and clinical features, the differential diagnosis may be
challenging. Recently, some authors suggested that functional dyspepsia (FD) and DG
could be different expressions of the same spectrum of gastric neuromuscular disorders,
with common histopathological alterations and comparable clinical manifestations and
prognosis [3].
In this review, we will discuss an update of dyspepsia and gastroparesis in patients
with diabetes, focusing on pathophysiology, clinical presentation and management of these
manifestations.
J. Clin. Med. 2021, 10, 1313. https://doi.org/10.3390/jcm10061313 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 1313 2 of 13
2. Dyspepsia: Definition and Clinical Classification
The term dyspepsia includes a set of symptoms with epigastric localization, which
can be episodic or persistent, with variable intensity and severity. In the clinical setting, it
is often difficult to characterize these symptoms and to distinguish dyspepsia from other
GI disorders such as gastroesophageal reflux disease (GERD) [4]. The American College
of Gastroenterology (ACG) and Canadian Association of Gastroenterology (CAG) clinical
guidelines give a useful definition of dyspepsia as predominant epigastric pain which lasts
at least one month and is associated with any other upper GI symptom such as epigastric
fullness, nausea, vomiting or heartburn [5].
For the appropriate clinical management, it is important to distinguish organic dys-
pepsia from FD. The former includes patients in whom clinical evaluation, laboratory tests,
endoscopy or radiologic studies can identify a pathologic process which is the cause of
dyspeptic symptoms, while FD includes all cases of dyspepsia without evidence of an
organic cause [6]. The exclusion of organic causes requires endoscopy and, where needed,
radiologic investigations, such as ultrasound or computed tomography, along with He-
licobacter pylori (H. pylori) testing and treating and re-evaluation of symptoms after its
eradication [7].
Functional dyspepsia can be classified on the basis of prevalent symptoms in post-
prandial distress syndrome (PDS) and epigastric pain syndrome (EPS) [8]. These two
entities, however, have blurred boundaries as they frequently overlap and they share
similar therapeutic strategies. Moreover, due to their common motility alterations, PDS is
more likely to overlap with gastroparesis.
Although different definitions of FD have been previously proposed, the most recent
update is represented by Rome IV criteria, shown in Table 1 [9].
Table 1. Rome IV diagnostic criteria of functional dyspepsia modified from [9].
Functional Dyspepsia:






2. Exclusion of structural disease which can explain symptoms
a. Must fulfill criteria for PDS (Postprandial Distress Syndrome) and/or EPS (Epigastric Pain Syndrome).
b. Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
Postprandial Distress Syndrome (PDS):
1. One or both of the following for at least 3 days per week and severe enough to impact on usual activities:
(a) postprandial fullness
(b) early satiation
2. No evidence of organic, systemic, or metabolic disease which can explain symptoms.
Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.
Supportive remarks:
• Possible co-existence of postprandial epigastric pain or burning, epigastric bloating, excessive belching.
• In case of vomiting, other disorders should be considered
• Possible association with heartburn
• Symptoms relieved by evacuation of feces or gas should not be ascribed to dyspepsia
Epigastric Pain Syndrome(EPS):
1. One or both of the following for at least 1 day per week and severe enough to impact on usual activities:
(a) epigastric pain
(b) epigastric burning
2. No evidence of organic, systemic, or metabolic disease which can explain symptoms
Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis
Supportive remarks:
• Pain may be induced or relieved by ingestion of a meal or may occur while fasting
• Possible coexistence of postprandial epigastric bloating, belching, and nausea
• In case of persistent vomiting, other disorders should be considered
• Possible association with heartburn
• Pain cannot be defined as biliary pain
• Symptoms relieved by evacuation of feces or gas should not be ascribed to dyspepsia
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H. pylori-associated dyspepsia represents a distinct form of dyspepsia [10]. If dys-
pepsia resolves six months after bacterial eradication it can be attributed to H. pylori
infection [11,12] otherwise the disorder is deemed FD [7].
2.1. Organic Dyspepsia
The most common cause of organic dyspepsia is peptic ulcer disease, which is often
associated with either H. pylori infection or chronic use of non-steroidal anti-inflammatory
drugs (NSAIDs) [6]. H. pylori is a Gram-negative, micro-aerophilic bacterium, usually
acquired during childhood, whose natural habitat is the luminal surface of the gastric
epithelium [13]. Since the human stomach is an unfriendly place for microbial survival,
H. pylori has developed a repertoire of acid resistance mechanisms which allow the mi-
croorganism to overcome the mucous layer. In particular, via the enzyme urease, the
bacterium creates a cloud of acid neutralizing chemicals around it, offering protection from
the acid [14]. H. pylori infection is accepted as the most important cause of gastritis and
PUD in humans. Moreover, it is recognized as a risk factor for gastric cancer [15] along
with potential involvement in the pathogenesis of several extra-gastric manifestations,
ranging from hematological diseases (such as idiopathic thrombocytopenic purpura, iron
deficiency anemia), to neurological diseases (for example, Parkinson’s disease and other
forms of neurodegeneration and dementia) [16–19].
Gastric or esophageal cancers are less frequent causes of dyspepsia. However, malig-
nancy has an important impact on prognosis and clinical management of affected patients
and should be ruled out in those aged 60 or over or with other risk factors [5]. Neoplastic
risk is increased in patients with H. pylori infection, family history of gastric malignancy,
previous gastric surgery, immigrants from endemic areas, smokers, patients with high
alcohol consumption or with a long history of heartburn [6]. Moreover, the risk of gas-
tric cancer is nearly doubled in males [5]. Pancreatic diseases, such as acute and chronic
pancreatitis, can present with dyspepsia too. Pancreatic pain, however, is often more
severe than epigastric pain related to dyspepsia, moreover chronic pancreatitis is usually
associated with weight loss and other symptoms due to pancreatic insufficiency [6]. Other
GI diseases associated with dyspepsia include gallstones, superior mesenteric artery syn-
drome, eosinophilic esophagitis, amyloidosis and lymphomas. The diseases that should be
considered in the differential diagnosis of dyspepsia are summarized in Table 2.
Table 2. Differential diagnoses of dyspepsia.
• ESOPHAGEAL DISEASES






• Erosive and non-erosive gastritis
• Helicobacter Pylori-related dyspepsia
• Gastroparesis
• Gastric cancer














• Connective tissue diseases (e.g., scleroderma)
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2.2. Functional Dyspepsia
The etiology of FD remains unclear. It is considered a multifactorial disease, related to
genetic, environmental, and socio-cultural factors [10,20]. The pathogenesis of FD involves
different mechanisms, such as delayed GE [21], gastric accommodation impairment [22],
hypersensitivity to gastric distention, altered chemosensitivity and altered duodenal sen-
sitivity to acids and lipids [6,23]. Impaired intestinal permeability is involved in FD
pathogenesis too and it is related to mucosal inflammation [23].
Intestinal physiological functions are modulated by GI endocrine mediators, such
as ghrelin, cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), motilin and glucose-
dependent insulinotropic peptide (GIP). These molecules influence mucosal immune
system, permeability and enteric nervous system (ENS) through endocrine and paracrine
mechanisms and might contribute to development of dyspepsia, even if more studies are
needed for a better understanding of their role in FD [10].
An emerging factor in FD development is the role of microbial imbalance of GI tract.
The term human microbiota is referred to the rich microbial community, consisting of
more than 1014 microorganisms, that colonizes the GI tract [24]. The perturbation of this
ecosystem as well as of mucosal integrity allows bacterial translocation and plays a key
role in the development of GI and systemic diseases [25–27]. Molecules produced by micro-
biota components can modify intestinal motility, and, at the same time, motility influences
microbiota composition. Moreover, bacterial mediators can act like neurotransmitters, thus
interacting with ENS. Gut microbiota and its mediators also influence intestinal permeabil-
ity [28]. They can modify the composition of the mucus layer and tight junctions through
modulation of genetic expression [10]. Moreover, alteration of the mucosal immune system,
inflammatory response and modification of gut microbiota after an acute gastroenteritis
can predispose to development of FD [12]. A previous GI infection is a risk factor for
irritable bowel syndrome (IBS) and FD development in about 10% of patients [29]. The role
of H. pylori in the development of FD is complex and controversial. Whilst the bacterium
induces alterations in gastric acid secretion, gut hormones production and motility [10],
studies have reported conflicting results regarding changes to post-prandial gastric motility
in H. pylori-infected patients [11].
As in other functional GI disorders, a central role in FD is played by the interaction
between the GI tract and central nervous system. The main site of this two-way effect
is amygdala, which is involved in emotions and pain and in satiety and fullness percep-
tion [10]. The brain-gut axis is structurally constituted by direct connections between the
central nervous system and myenteric plexus. It is through this pathway that emotion
can influence GE, intestinal motility, mucosal secretion and barrier function. Conversely,
mental function can be influenced by GI motility, visceral inflammation and injury [8].
As a result of this interaction, mood disorders and psycho-social factors have a demon-
strated relationship with both FD development and reduction in quality of life of these
patients [23]. Therefore, FD and other functional GI disorders can be defined as the result
of the interaction of biopsychosocial factors and gut physiology through the brain-gut axis.
3. Dyspepsia in Diabetic Patients
Dyspeptic symptoms are a frequent finding in patients with diabetes and they are
part of the so-called diabetic enteropathy (DE), which includes the GI manifestations of
DM [30]. Autonomic neuropathy has an important pathogenetic role in DE, together
with interstitial cells of Cajal depletion and reduced expression of neuronal nitric oxide
syntethase [30]. These alterations lead to abnormal GI motility, causing symptoms such as
dyspepsia, nausea, vomiting, constipation and fecal incontinence.
Despite the high incidence of dyspepsia in patients with diabetes, the current literature
offers limited data about the clinical features and the appropriate management of dyspepsia
in this population. In case of a patient with DM presenting with upper GI symptoms,
organic disease and medication side effects should be excluded: GLP-1 analogues, for
example, can cause nausea and vomiting [30]. Moreover, DG should be excluded through
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GE measurement, as discussed below [2,31]. When organic dyspepsia, medication side
effects and DG are excluded, the clinical management is analogous to that of non-diabetic
patients, except for a more important therapeutic role of prokinetics in patients with DM.
4. H. pylori Infection in Patients with Diabetes
Many studies have analyzed the prevalence of H. pylori infection in symptomatic
and asymptomatic patients with DM [32–34]. Hyperglycemia has been suggested as a
predisposing factor for H. pylori colonization [32]. A recent case–control serological study
demonstrated a significantly higher prevalence of H. pylori infection in patients with DM,
who had positive antibody titers in 50.7% of cases, compared to 38.2% of controls [33].
Moreover, H. pylori positive patients showed higher incidence of GI symptoms, including
bloating, distention, vomiting, abdominal pain, constipation and diarrhea, as well as sys-
temic manifestations such as hypertension, muscular symptoms and chronic bronchitis,
which is potentially attributable to H. pylori contribution to inducing systemic inflamma-
tion [33].
Among patients with DM, H. pylori infection has been shown to be higher in patients
with gastroparesis, and bacterial eradication reduced symptoms such as upper abdominal
pain and distention, early satiety and anorexia [34], thus suggesting a pathogenetic role of
H. pylori in DG and reaffirming the therapeutic role of its eradication.
5. Diabetic Gastroparesis
DG is characterized by upper GI symptoms, such as epigastric distress, nausea, vom-
iting, early satiety or bloating, which occur in DM in the absence of organic obstruction.
Epidemiologic studies about DG show heterogeneous data: in a study, among type 1 and
type 2 diabetic patients with GI symptoms, the incidence of documented gastroparesis
was 60% [35], while a more recent community-based study showed a ten-year cumulative
incidence of gastroparesis of 5.2% in type 1 diabetes versus 1% in type 2 diabetes [36].
Whilst GE is often delayed in gastroparesis, the entity of motility alteration has a poor
correlation with the severity of symptoms [37].
Glycemic control plays a key role in DG as it influences GE [2,38]. Severe acute
hyperglycemia, in fact, has shown to delay GE in both healthy subjects and patients within
type 1 DM, while its effects in type 2 diabetes are not clear [38,39]. Moreover, a prospective,
observational, follow-up study showed that baseline levels of glycated hemoglobin (HbA1c)
and duration of DM at baseline were independently associated with delayed GE, thus
supporting a relationship between long-term hyperglycemic exposure and GE [40]. A
subsequent cross-sectional study involving 147 type 2 diabetics confirmed the correlation
of DG with blood glucose levels, HbA1c and duration of diabetes [41]. Currently, there
are limited data on the long-term impact of improving glycemic control on patients with
GE [38,42].
One of the main pathogenetic mechanisms of DG is autonomic neuropathy, charac-
terized by loss of cells in motor and sensory sympathetic ganglia and structural changes
of vagal nerve fibers, such as demyelination and axonal degeneration. These alterations
often are multifocal, suggesting an ischemic injury [2]. Alterations in ENS and gut wall
contribute to development of DG too and are a result of different processes, including
apoptosis, oxidative stress, advanced glycation end products, and neuroimmune mecha-
nisms [2]. Histological findings in both diabetic and non-diabetic gastroparetic patients
showed loss of interstitial cells of Cajal (ICCs) and ganglion cells, fibrosis of the pylorus and
lymphocytic infiltration around myenteric plexus [37]. Notably, gastroparesis and FD show
the same histopathologichal changes, such as reduction of ICCs and anti-inflammatory
C206+ macrophages, as demonstrated by histologic examination of full-thickness stomach
biopsies [3]. These findings suggest a common pathophysiology and a possible target for
new therapies, focused on the pathogenic mechanism of these diseases instead of mere
symptom relief.
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Comorbid abdominal pain with gastroparesis, has been related to visceral hypersensi-
tivity, however, this symptom may be partly unrelated to gastric sensorimotor dysfunction.
In a study of 32 patients with gastroparesis, 20 with comorbid DM, more than 60% had
positive Carnett’s sign, which indicates somatic rather than visceral pain, and about half of
them were hypervigilant to pain. Furthermore, more than one-third of these patients met
criteria for neuropathic pain [43].
As in FD and other functional disorders [44], DG is associated with depression. In
comparison with general population, diabetic patients have a higher prevalence of de-
pression [45], which is often severe and has shown to play a role in expression of GI
sensorimotor dysfunctions [2]. On the other side, DG has a negative impact on patients’
quality of life, with increased anxiety and depression [2].
In patients with DM and upper GI symptoms, gastroparesis can be diagnosed by the
presence of delayed GE without gastric outlet obstruction [2]. The gold standard to define
and quantify delayed GE is scintigraphy [46], during the test a solid radiolabeled meal is
administered to the patient and a series of scintigraphic images is acquired: delayed GE is
diagnosed if more than 60% of the meal is retained at 2 h or more than 10% of the meal is
retained at 4 h [47]. GE scintigraphy, however, can be expensive and exposes patients to
radioactivity. Moreover, GE is delayed by hyperglycemia, therefore, blood glucose levels
should be controlled at the moment of the test. Ideally, glycemia should be lower than
200 mg/dL, if it is higher than 275 mg/dL the test cannot be performed or, in alternative,
insulin should be administered to lower blood glucose levels [47].
An alternative, non-radioactive method for delayed GE documentation is the 13C-
octanoic acid breath test [48], which has shown a strong correlation with GE scintigraphy
in diabetic populations [46,49]. Hence, 13C-octanoic acid breath test represents a suitable
alternative to investigate delayed GE in patients with DM in clinical practice.
Although many patients with DM have abnormal GE, few develop overt clinical symp-
toms, furthermore, part of symptomatic diabetics has little or no delay in GE. Differential
diagnosis between gastroparesis and FD may be challenging, however, a delayed GE, the
presence of vomiting and a lack of response to prokinetics are more suggestive of DG rather
than of FD [10].
6. Clinical Management of Dyspepsia
The ACG/CAG clinical guidelines [5] provide indications on the diagnostic work-up
which should be performed in patients with dyspeptic symptoms in addition to phar-
macological therapies. According to guidelines, patients under the age of 60 should not
undergo endoscopy to exclude malignancy, while, as previously mentioned, upper GI
neoplasia should be excluded in elderly and in subjects with neoplastic risk factors [5].
The ACG/CAG clinical guidelines do not recommend the routine use of motility studies,
which should only be performed in case of FD when gastroparesis is strongly suspected,
as in patients with predominant symptoms of nausea and vomiting, who do not respond
to empiric therapy. As discussed above, gastroparesis is diagnosed by documentation of
delayed GE, investigated through GE scintigraphy or 13C-octanoic acid breath test, after
exclusion of mechanical obstruction through radiologic or endoscopic examination [5].
Patients under the age of 60 should have a non-invasive test for H. pylori infection and
they should be subsequently treated if the test is positive, while they should receive an
empirical treatment with proton pump inhibitors (PPIs) if they are H. pylori negative or
they are still symptomatic after bacterial eradication [5]. Even in the absence of gastric acid
secretion abnormalities, PPIs showed to be effective in relieving FD symptoms and their
efficacy was not related to concomitant GERD or H. pylori positivity [50].
Patients with dyspepsia not responding to PPIs and H. pylori eradication, can be offered
a prokinetic therapy, despite the limited effectiveness data only available in non-diabetic
dyspeptic patients [5]. However, only in dyspepsia related to DE, prokinetics have shown
efficacy in improving gastric motility and reducing symptoms [30]. Prokinetics include
serotonin-4 receptor agonists such as cisapride, mosapride and tandospirone citrate, which
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can be effective in relieving abdominal pain [51] and dopamine-2 receptor antagonists,
like metoclopramide, which have shown efficacy similar to cisapride in improving GE
and a better control of nausea, vomiting and early satiety [52]. However, metoclopramide
is associated with important side effects, including hyperprolactinemia, closely related
to gynecomastia and galactorrhea, and extrapyramidal symptoms, such as drug-induced
parkinsonism and tardive dyskinesia [2].
Acotiamide is a prokinetic, currently approved for use in Japan and India for FD.
It inhibits pre-sinaptic acetil-cholinesterase and antagonized presynaptic M1 and M2
receptors and it seems to relieve PDS symptoms, with a good tolerability [53,54].
An alternative to prokinetic drugs is represented by neuromodulators. In fact, triciclic
antidepressant therapy (TCAs), such as amitriptyline, showed to relieve abdominal pain
and improve the quality of life in patients with dyspepsia [55,56]. Data on serotonin
reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs)
are controversial as some studies showed an efficacy similar to TCAs [57], while other
studies did not demonstrate any efficacy in symptom relief [53]. In the clinical setting the
decision between prokinetics and TCAs should be made on a case-by-case basis [5].
As previously discussed, microbiota is receiving increasing attention in the context
of FD and some authors have studied a potential effect of therapies targeting on gut
microbiota, such as rifaximin [58] or supplementation with Lactobacillus strains [59],
which act restoring the physiological microbiota. However, data about the indication to
treat dyspeptic patients with probiotics remain scarce.
Finally, patients with FD not responding to drug therapy should be offered psycho-
logical therapies. Considering the role of psychological factors in the development of FD,
in fact, these treatments may provide a significant symptom relief [10]. The quality of
evidence about this approach is very low and the available studies are heterogeneous and
do not suggest a specific psychological intervention [5].
Some authors have also proposed complementary and alternative treatments, such
as herbal supplements, acupuncture and hypnosis [10], however, the available data are
limited and more studies are needed to assess the efficacy of these therapies.
The above discussed therapeutic options for FD are summarized in Figure 1. Together
with these pharmacological and non-pharmacological approaches, remains crucial the
therapeutic role of lifestyle modifications, such as weight loss in obese patients, cessation
of smoking, diet variations, NSAIDs avoidance [10]. These interventions represent the first
step in FD treatment and should be associated with any other therapy.
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7. Clinical Management of Gastroparesis
In regard to DG, a stepwise therapeutic approach is also recommended. There is a
scarcity of data on appropriate dietary intervention with much of the data extrapolated
from other conditions. Typically, dietary advice commences with a low-fat, low-fiber diet
but may require liquid meals, enteral or parenteral nutritional support. Avoidance of drugs
which delay GE, such as GLP-1 analogues and opioids is recommended [2]. As above
described, higher glycemic levels are associated with delayed GE: an accurate glycemic
control is therefore essential in the clinical management of DG. However, data on long-term
improvement in terms of glycemic control are limited [38,42].
Prokinetic drugs, including metoclopramide and erythromycin represent the first-line
therapy. Metoclopramide proved to significantly reduce symptoms of DG through both
central antagonism on dopamine receptors and peripheral cholinergic effect [2], but its use
is limited by the previously described side effects. Domperidone is a peripheral dopamine
receptor antagonist with prokinetic effect, which showed to improve symptoms, with a
positive effect sustained over time [2]. As domperidone does not cross the blood–brain
barrier, the risk of hyperprolactinemia and extrapyramidal symptoms is significantly lower
in comparison with metoclopramide. On the other side, it should be administered with cau-
tion in patients with impaired liver function or at increased risk of cardiac events (such as
prolonged QT interval) and its co-administration with QT-prolonging drugs is contraindi-
cated [2]. As regards erythromycin, early studies showed a significant reduction in the
total symptom score after acute intravenous and chronic oral administration [60], however
further investigatio s demonstrated that its long-ter efficacy is often limited by devel-
opment of tachyphylaxis [60,61]. M reo , erythromycin is associated with potentially
severe adverse event , such as QT prolongati n and ventri ular arrhythmia [60,62].
P ucalopr de i a serotonin receptor agonist which i mainly used in the treatment
of constipation. Recently, a randomized placebo-controlled study analyzed its efficacy in
thirty-four patients with DG: prucalopride significantly reduced GE time and improved
symptoms, evaluated through Gastroparesis Cardinal Symptom Index [63]. Thes data are
promising, but still need to be confirmed in lar er sample studi s.
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Additionally, antiemetics are useful for symptom control in patients with DG. Among
them, aprepitant, a neurokinin-1 inhibitor, showed to increase gastric accommodation and
reduce nausea and vomiting in DE, even if it had no effect on GE [62].
Agonists of ghrelin and 5-hydroxytryptophan receptors, which are still experimental,
are giving promising results [2,37]. Relamorelin is a ghrelin agonist administered by
subcutaneous injection, which showed to reduce symptoms and increase GE half-time
in phase 2 trials [2,64]. Its main side effect was glycemic control impairment, with more
frequent hyperglycemia episodes and higher HbA1c levels [2,64].
As above mentioned, a better comprehension of pathogenic mechanisms of DG could
lead to new effective therapies. One of these possible research targets is represented by
micro-RNAs. MiR-10b-5p regulates development and function of ICCs and pancreatic β
cells through the KLF11-KIT pathway, in murine models, knockout of mir-10b in KIT+
cells led to DM and gastroparesis [65]. In these mice, injection of miR-10b-5p mimic or
Klf11 small interfering RNAs were effective in improving glucose homeostasis and gastric
motility [65], thus suggesting a potential therapeutic role of micro-RNAs.
As concerns the possible role of alternative medicine in DG, cannabinoids use has been
suggested because of their positive effects on chemotherapy-induced nausea and vomiting.
However, there are no studies investigating the use of synthetic or herbal cannabinoids
in the symptomatic treatment of dyspepsia or gastroparesis [66]. Acupuncture, instead,
showed promising results in improving gastric emptying in both murine models and
human studies [66]. Its effects seem to be mediated by vagal activity, but other mechanisms
could be involved [66]. In murine models, in fact, electroacupuncture was associated with
reduced apoptosis and increased proliferation of ICCs [67].
In refractory DG, more invasive therapeutic approaches should be considered and
evaluated on a case-by-case basis. These treatments include supplemental nutrition, prefer-
ably enteral, administered through a feeding jejunostomy, gastric electric stimulation,
pyloromyotomy, and sleeve or total gastrectomy [2,38].
Hospital admission should be considered in case of gastroparesis associated to re-
fractory vomiting, dehydration, electrolyte abnormalities and malnutrition [68]. Clinical
management of hospitalized patients requires pharmacological control of symptoms, intra-
venous hydration, electrolyte correction, glucose control and nutritional support. Enteral
nutrition should be preferred, even if in case of severe DG gastric feeding is often not toler-
ated, thus a nasoduodenal or nasojejunal tube placement can be necessary [68]. Although
enteral nutrition should be the first choice, short-term parenteral nutrition may be needed
for selected patients, when nasoenteric tube placement or feeding is not tolerated or is
contraindicated [68].
Figure 2 shows a therapeutic algorithm for DG, which includes the above discussed
treatment options.




Figure 2. Treatment algorithm for diabetic gastroparesis. 
8. Conclusions 
FD and gastroparesis are characterized by a complex pathogenesis whose mecha-
nisms remain unclear. This is even more true for patients with diabetes who often suffer 
from these disturbances. As a consequence, their management should be based initially 
on international guidelines and tailored to their individual needs. Well-designed studies 
are needed in this field. 
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